Zimmer Biomet remains the global leader for knee replacement and hip replacement sales. However, the company’s lead over the competition has eroded over the last decade due to changing market conditions and evolving technology requirements.
For example, Zimmer Biomet’s global knee franchise was 85% larger than Stryker’s in 2016, $2.752 billion versus $1.49 billion respectively. That lead shrank to 30% by 2024, $3.173 billion versus $2.447 billion.
Zimmer Biomet’s U.S. knee and hip sales are a major reason for the company’s shrinking lead over its peers. Sales for both segments were flat or declined from 2016 through 2020.
Performance has been better over the last five years, but gains have been incremental. Zimmer Biomet’s 10-year CAGR for U.S. knees and hips is just over 1%, meaningfully below market growth.
There are reasons for optimism, however, especially in knee replacement. The third quarter is off to a strong start and Zimmer Biomet is seeing returns on its direct-to-patient initiatives. The company made leadership changes and restructured some territories in addition to evolving its incentive plan.
The Persona OsseoTi cementless total knee and Oxford partial cementless knee are helping drive conversions of surgeons from competitive systems.
“Things are moving in the right direction, encouraged by not satisfied,” said Zimmer Biomet CEO Ivan Tornos. “We want to get back to the days where we’re taking share each and every quarter. We do believe there’s a pathway there through new product introductions down the road, technology like Monogram, technology like the investments we’re making on smart implants.”
Zimmer Biomet U.S. Knee and Hip Replacement Sales
Zimmer Biomet remains the global leader for knee replacement and hip replacement sales. However, the company's lead over the competition has eroded over the last decade due to changing market conditions and evolving technology requirements.
For example, Zimmer Biomet's global knee...
Zimmer Biomet U.S. Knee and Hip Replacement Sales
Zimmer Biomet remains the global leader for knee replacement and hip replacement sales. However, the company’s lead over the competition has eroded over the last decade due to changing market conditions and evolving technology requirements.
For example, Zimmer Biomet’s global knee franchise was 85% larger than Stryker’s in 2016, $2.752 billion versus $1.49 billion respectively. That lead shrank to 30% by 2024, $3.173 billion versus $2.447 billion.
Zimmer Biomet’s U.S. knee and hip sales are a major reason for the company’s shrinking lead over its peers. Sales for both segments were flat or declined from 2016 through 2020.
Performance has been better over the last five years, but gains have been incremental. Zimmer Biomet’s 10-year CAGR for U.S. knees and hips is just over 1%, meaningfully below market growth.
There are reasons for optimism, however, especially in knee replacement. The third quarter is off to a strong start and Zimmer Biomet is seeing returns on its direct-to-patient initiatives. The company made leadership changes and restructured some territories in addition to evolving its incentive plan.
The Persona OsseoTi cementless total knee and Oxford partial cementless knee are helping drive conversions of surgeons from competitive systems.
“Things are moving in the right direction, encouraged by not satisfied,” said Zimmer Biomet CEO Ivan Tornos. “We want to get back to the days where we’re taking share each and every quarter. We do believe there’s a pathway there through new product introductions down the road, technology like Monogram, technology like the investments we’re making on smart implants.”
You are out of free articles for this month
Subscribe as a Guest for $0 and unlock a total of 5 articles per month.
You are out of five articles for this month
Subscribe as an Executive Member for access to unlimited articles, THE
ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.
Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.
Copy to clipboard 
